Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
CEO J. Michael Pearson returns to crisis-ridden Valeant |
||||||||||||||||||
After a two-month medical leave brought on by a bout of pneumonia, Valeant ($VRX) CEO J. Michael Pearson returned on Sunday, arriving at the embattled pharma that would only see more trouble as the week went on. In Pearson's first week back, Valeant scrapped its 2016 guidance, delayed fourth-quarter results, disclosed a threat to Xifaxan and confirmed it's being investigated by the SEC. Those issues accompany older problems the company faces, including its admittance of accounting missteps, a congressional drug pricing investigation, and questions regarding its relationship with specialty pharmacy Philidor. Pearson took his medical leave in late December, leaving Valeant's ex-CFO Howard Schiller to fill in for much of the absence. The company also announced this week that interim chairman Robert Ingram will fill that role. Pearson said on Sunday that he plans to build relationships with payers, regulators and government officials, "while improving Valeant's reporting procedures, internal controls and transparency." Story
|